Saracatinib

Product ID S0168

Cas No. 379231-04-6

Purity ≥98%

Unit Size	Cost	Quantity		Stock

Bulk Quote

Add to Wishlist

Quicklinks

Description
Product Info
Shipping and Storage
Downloads
References

Description
Product Info
Shipping and Storage
Downloads
References
Custom Order

Description

Saracatinib is an inhibitor of Src and Abl family kinases that is used for its anticancer chemotherapeutic and immunomodulatory benefits. Saracatinib is currently in clinical trials as a potential treatment for a variety of cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, gastric cancer, and myeloma. In cellular and animal models, this compound inhibits migration, invasion, and growth of cancer cells. Additionally, saracatinib displays mixed immunomodulatory effects, decreasing T cell cytokine production in one in vitro model and increasing CD8+ memory T cells and production of IFN-γ in another in vitro model.

Product Info

Cas No.	379231-04-6
Purity	≥98%
Formula	C₂₇H₃₂ClN₅O₅
Formula Wt.	542.03
Chemical Name	N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-4-quinazolinamine
IUPAC Name	N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(oxan-4-yloxy)quinazolin-4-amine
Synonym	AZD-0530
Appearance	Off white powder

Shipping and Storage

Store Temp	Ambient
Ship Temp	Ambient

Downloads

MSDS	S0168 MSDS PDF
Info Sheet	S0168 Info Sheet PDF

References

Gangadhar TC, Clark JI, Karrison T, et al. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs. 2013 Jun;31(3):769-73. PMID: 23151808.

Nam HJ, Im SA, Oh DY, et al. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer. Mol Cancer Ther. 2013 Jan;12(1):16-26. PMID: 23144237.

Cavalloni G, Peraldo-Neia C, Sarotto I, et al. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas. Mol Cancer Ther. 2012 Jul;11(7):1528-38. PMID: 22452946.

Takai S, Sabzevari H, Farsaci B, et al. Distinct effects of saracatinib on memory CD8+ T cell differentiation. J Immunol. 2012 May 1;188(9):4323-33. PMID: 22450814.